GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Biosyent Inc (OTCPK:BIOYF) » Definitions » Forward PE Ratio
中文

Biosyent (Biosyent) Forward PE Ratio : 18.35 (As of Apr. 25, 2024)


View and export this data going back to . Start your Free Trial

What is Biosyent Forward PE Ratio?

Biosyent's Forward PE Ratio for today is 18.35.

Biosyent's PE Ratio without NRI for today is 15.86.

Biosyent's PE Ratio for today is 15.94.


Biosyent Forward PE Ratio Historical Data

The historical data trend for Biosyent's Forward PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biosyent Forward PE Ratio Chart

Biosyent Annual Data
Trend 2015-12 2016-12 2017-12 2018-12 2019-12 2020-12 2021-12 2022-12 2023-12 2024-04
Forward PE Ratio
20.04 24.33 22.73 17.79 16.29 21.88 18.42 13.07 17.73 18.35

Biosyent Quarterly Data
2016-12 2017-03 2017-06 2017-09 2017-12 2018-03 2018-06 2018-09 2018-12 2019-03 2019-06 2019-09 2019-12 2020-03 2020-06 2020-09 2020-12 2021-03 2021-06 2021-09 2021-12 2022-03 2022-06 2022-09 2022-12 2023-03 2023-06 2023-09 2023-12 2024-03
Forward PE Ratio 24.33 22.99 25.84 21.93 22.73 23.81 23.36 20.53 17.79 17.12 15.13 16.05 16.29 11.34 14.53 19.80 21.88 19.01 24.27 16.69 18.42 18.28 16.10 14.22 13.07 11.76 16.98 20.96 17.73 18.45

Competitive Comparison of Biosyent's Forward PE Ratio

For the Drug Manufacturers - Specialty & Generic subindustry, Biosyent's Forward PE Ratio, along with its competitors' market caps and Forward PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Biosyent's Forward PE Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Biosyent's Forward PE Ratio distribution charts can be found below:

* The bar in red indicates where Biosyent's Forward PE Ratio falls into.



Biosyent Forward PE Ratio Calculation

It's a measure of the price-to-earnings ratio (PE Ratio) using forecasted earnings for the calculation. While the earnings used are just an estimate and are not as reliable as current earnings data, there is still benefit in estimated P/E analysis. The forecasted earnings used in the formula can either be for the next 12 months or for the next full-year fiscal period.


Biosyent  (OTCPK:BIOYF) Forward PE Ratio Explanation

The Forward PE Ratio of a company is often used to compare current earnings to estimated future earnings, as well as gaining a clearer picture of what earnings will look like without charges and other accounting adjustments. If earnings are expected to grow in the future, the Forward PE Ratio will be lower than the current PE Ratio. This measure is also used to compare one company to another with a forward-looking focus.

Trailing PE Ratio relies on what is already done. It uses the current share price and divides by the total EPS (Basic) over the past 12 months. PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio .


Biosyent Forward PE Ratio Related Terms

Thank you for viewing the detailed overview of Biosyent's Forward PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Biosyent (Biosyent) Business Description

Traded in Other Exchanges
Address
2476 Argentia Road, Suite 402, Toronto, Mississauga, ON, CAN, L5N 6M1
Biosyent Inc is a Canada-based growth-oriented specialty pharmaceutical company. It has focused on in-licensing or acquiring originative pharmaceuticals and other healthcare products. Its product includes FeraMAX 150, Cathejell Jelly, FeraMAX Powder, RepaGyn, Proktis-M, Repagyn, and Tibella.

Biosyent (Biosyent) Headlines

From GuruFocus

BioSyent Initiates First Dividend

By GlobeNewswire GlobeNewswire 10-12-2022

BioSyent Announces Grant of Restricted Share Units

By GlobeNewswire GlobeNewswire 03-31-2023

BioSyent to Present at The LD 500 Virtual Conference

By ACCESSWIRE ACCESSWIRE 08-25-2020

BioSyent Announces Changes to Executive Management

By GlobeNewswire GlobeNewswire 09-10-2018

BioSyent to Present at Upcoming Investor Conferences

By GlobeNewswire GlobeNewswire 04-25-2018

When Being Certain Isn't Enough

By Thomas Macpherson Thomas Macpherson 08-30-2019

BioSyent Announces Adoption of Restricted Share Unit Plan

By GlobeNewswire GlobeNewswire 03-06-2020

BioSyent Schedules Q2 and H1 2022 Earnings Release for August 23, 2022

By GlobeNewswire GlobeNewswire 08-17-2022

BioSyent Announces Approval of New Product

By GlobeNewswire GlobeNewswire 05-31-2023